The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials (Q26852293)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2014

Language	Label	Description	Also known as
English	The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials	scientific article published in July 2014

Statements

scholarly article

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials (English)

1 reference

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D. Sanford

1

1 reference

A. Naidu

2

1 reference

N. Alizadeh

3

1 reference

A. Lazo-Langner

4

1 reference

language of work or name

1 reference

publication date

July 2014

1 reference

Journal of Thrombosis and Haemostasis

1 reference

12

1 reference

7

1 reference

1076-85

1 reference

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Alternatively spliced tissue factor induces angiogenesis through integrin ligation.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Inhibition of tissue factor signaling suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Heparin and chemotherapy in the management of inoperable lung carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Allocation concealment in randomised trials: defending against deciphering

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

21 January 2018

Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12595

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1111/JTH.12595

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_ihkjaveaorbullgxysjcd5q3ka

1 reference

https://api.fatcat.wiki/v0/release/ihkjaveaorbullgxysjcd5q3ka

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26852293&oldid=1840064131"